IPI targets neurexin with upcoming antibody suite
Synaptic function involves the interactions of hundreds, maybe thousands, of different proteins. A particular family,…
Epitope tag antibodies, plasmids and data transparency: A Q&A with Mike Walden
In 2024, the Institute for Protein Innovation (IPI) released a set of antibodies targeting nine…
Year in review: Looking back on 2024
It’s been a whirlwind year here at IPI, from antibody releases to workshops and lab…
Michael Walden bridges two worlds as IPI’s commercial director
Driving commercial development at a nonprofit institution is a challenge. The business models are complex…
Glypicans: Explained
Hundreds of millions of years before humans evolved, a family of proteins came to be…
Deborah Moshinsky’s enterprising behind-the-scenes efforts ensure antibody quality
Deborah “Deb” Moshinsky is the type of process-motivated scientist that all labs require — but…
IPI’s Antibodies Roadshow fosters neuroscience collaborations
The Institute for Protein Innovation (IPI) kicked off its inaugural “Antibodies Roadshow” on Saturday, October…
Community validation effort draws inspiration from famed HLDA workshops
The Institute for Protein Innovation (IPI), typically quiet on a Sunday afternoon, buzzed with excitement…
IPI plasmids offer a build-your-own-antibody tool to protein researchers
True to its mission to accelerate research through the advancement of protein science, the Institute…
From our president and CEO: “Complex problems require collaboration”
The mission of the Institute for Protein Innovation is to advance protein science and technology…
Bespoke high-throughput approach expedites screening of cell-surface ectodomains
Cell-surface receptors are notoriously tricky to produce and purify; they misfold, aggregate, degrade, and often…
Panel highlights antibody characterization and validation strategies
Biology’s shortage of high-quality, well-performing and easily accessible antibodies is no breaking news; it’s a…